Abstract:P90 ribosomal S6 kinase 2 (RSK2) is an important member of the RSK family, functioning as a kinase enzyme that targets serine and threonine residues and contributes to regulating cell growth. RSK2 comprises two major functional domains: the N-terminal kinase domain (NTKD) and the C-terminal kinase domain (CTKD). RSK2 is situated at the lower end of the Mitogen-activated protein kinases (MAPK) signaling pathway and is phosphorylated by the direct regulation of Extracellular signal-regulating kinase (ERK). RSK2 has been found to play a pivotal role in regulating cell proliferation, apoptosis, metastasis, and invasion in various cancer cells, including breast cancer and melanoma. Consequently, RSK2 has emerged as a potential target for the development of anti-cancer drugs. Presently, several inhibitors are undergoing clinical trials, such as SL0101. Current inhibitors of RSK2 mainly bind to its NTK or CTK domains and inhibit their activity. Natural products serve as an important resource for drug development and screening and with the potential to identify RSK2 inhibitors. This article discusses how RSK2 influences tumor cell proliferation, prevents apoptosis, arrests the cell cycle process, and promotes cancer metastasis through its regulation of downstream pathways or interaction with other biological molecules. Additionally, the paper also covers recent research progress on RSK2 inhibitors and the mechanisms of action of natural RSK2 inhibitors on tumors. This review emphasizes the significance of RSK2 as a potential therapeutic target in cancer and offers a theoretical basis for the clinical application of RSK2 inhibitors.

Targeting RSK2 in Cancer Therapy: A Review of Natural Products

RSK2 and its binding partners in cell proliferation, transformation and cancer development

Promising Natural Products Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy.

A Regulatory Mechanism for RSK2 NH(2)-terminal Kinase Activity.

Discovery of novel p90 ribosomal S6 kinase 2 inhibitors for potential cancer treatment through ligand-based and structure-based virtual screening methods

Exploration of Potential RSK2 Inhibitors by Pharmacophore Modelling, Structure-Based 3D-QSAR, Molecular Docking Study and Molecular Dynamics Simulation

Synergistic Anticancer Effect by Targeting CDK2 and EGFR-ERK Signaling.

Natural products and derivatives in renal, urothelial and testicular cancers: targeting signaling pathways and therapeutic potential

Rsk2 Protects Human Breast Cancer Cells Under Endoplasmic Reticulum Stress Through Activating Ampk Alpha 2-Mediated Autophagy

RSK2 protects human breast cancer cells under endoplasmic reticulum stress through activating AMPKα2-mediated autophagy

Small-molecule compounds inhibiting S-phase kinase-associated protein 2: A review

Targeting Extracellular Signal-Regulated Protein Kinase 1/2 (ERK1/2) in Cancer: an Update on Pharmacological Small-Molecule Inhibitors.

The role of targeting kinase activity by natural products in cancer chemoprevention and chemotherapy (Review)

Discovery of a novel dual-target inhibitor against RSK1 and MSK2 to suppress growth of human colon cancer

Targeting RAS-RAF-MEK-ERK Signaling Pathway in Human Cancer: Current Status in Clinical Trials.

Inhibiting Eukaryotic Elongation Factor 2 Kinase: An Update on Pharmacological Small-Molecule Compounds in Cancer

The Skp2 Pathway: A Critical Target for Cancer Therapy

Cancer metabolism control by natural products: Pyruvate kinase M2 targeting therapeutics

Synthesis and Anti-Tumor Activity Evaluation of 1H-Pyrrolo[2,3-b]pyridine-2-carboxamide Derivatives with Phenyl Sulfonamide Groups As Potent RSK2 Inhibitors

Ribosomal protein S6 kinase 2 (RPS6KB2) is a potential immunotherapeutic target for cancer that upregulates proinflammatory cytokines

Receptor Tyrosine Kinases: Biological Functions and Anticancer Targeted Therapy